Supplementary Materials

Supplementary Material for:

Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β

Kevin M. Hart, Thomas Fabre, Joshua C. Sciurba, Richard L. Gieseck III, Lee A. Borthwick, Kevin M. Vannella, Thomas H. Acciani, Rafael de Queiroz Prado, Robert W. Thompson, Sandra White, Genevieve Soucy, Marc Bilodeau, Thirumalai R. Ramalingam, Joseph R. Arron, Naglaa H. Shoukry, Thomas A. Wynn*

*Corresponding author. Email: twynn{at}niaid.nih.gov

Published 28 June 2017, Sci. Transl. Med. 9, eaal3694 (2017)
DOI: 10.1126/scitranslmed.aal3694

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Chronic HFD–induced NASH is associated with hepatic ballooning and activation of fibroblasts.
  • Fig. S2. Analysis of adipose tissue fibrotic pathways and collagen deposition.
  • Fig. S3. IL-10 in mouse and human NASH.
  • Fig. S4. NAFLD/NASH in 40-week HFD-challenged WT, IL-4, and IL-10/IL-4 knockout mice.
  • Fig. S5. Comparison of IL-10 versus IL-12 deletion in NAFLD progression.
  • Fig. S6. Adipose tissue inflammation in IFN-γ knockouts on HFD.
  • Fig. S7. Presence of cellular mediators of inflammation in NAFLD/NASH.
  • Fig. S8. IL-10/IL-4 knockout animals have long-term protection from HFD-induced NASH.
  • Fig. S9. Collagen- and eosinophil-associated chemoattractant expression alterations in patient biopsies.
  • Fig. S10. Representative histological eosinophils in NASH patient biopsies.
  • Fig. S11. Inflammatory pathways in NASH progression.
  • Legend for table S1

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S1 (Microsoft Excel format). Primary data.